{
    "clinical_study": {
        "@rank": "122810", 
        "arm_group": [
            {
                "arm_group_label": "G3041", 
                "arm_group_type": "Experimental", 
                "description": "Amlodipine orotate 10mg/Olmesartan medoxomil 40mg"
            }, 
            {
                "arm_group_label": "SEVIKAR\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "Amlodipine besylate 10mg/Olmesartan medoxomil 40mg"
            }
        ], 
        "brief_summary": {
            "textblock": "Study Design : randomized, open label, single-dose, 2-way cross-over design\n\n      Phase : Phase I"
        }, 
        "brief_title": "Pharmacokinetic/Pharmacodynamic & Safety Study of G3041 and SEVIKAR\u00ae Tablet in Healthy Adult Volunteers", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Adult Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  healthy volunteers between the ages of 19 to 55 years old\n\n          -  19 \u2264 BMI \u2264 27\n\n          -  having neither congenital/chronic diseases nor pathological symptoms/findings as\n             results of medical examination\n\n          -  doctor determines to be suitable as subjects within 4 weeks ago before administration\n\n        Exclusion Criteria:\n\n          -  Hypersensitivity(or history of hypersensitivity) to amlodipine and olmesartan\n\n          -  Exceed 1.5 times of the upper limit of the reference range of AST, ALT, total\n             bilirubin, \u03b3-GT\n\n          -  Excessive drinking(exceed alcohol 140g/week)\n\n          -  Excessive caffeine(exceed 4cups/day) and  grape fruit/orange juice(exceed 1cup/day)\n\n          -  Smoking over 10 cigarettes per day"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02058472", 
            "org_study_id": "G3041_BE_I"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "G3041", 
                    "SEVIKAR\u00ae"
                ], 
                "intervention_name": "G3041", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "G3041", 
                    "SEVIKAR\u00ae"
                ], 
                "intervention_name": "SEVIKAR\u00ae", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 6, 2014", 
        "number_of_arms": "2", 
        "official_title": "An Open Label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetic/Pharmacodynamic Characteristics and Safety Following Administration of G3041 and SEVIKAR\u00ae Tablet in Healthy Adult Volunteers", 
        "overall_official": {
            "affiliation": "Samsung Medical Center", 
            "last_name": "JW Ko, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "South Korea : Korea Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "AUClast, Cmax", 
            "safety_issue": "No", 
            "time_frame": "Blood gathering point : 0h, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 7h, 8h, 12h, 24h, 48h, 72h"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02058472"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "tmax, t1/2, AUCinf, CL/F, Vz/F", 
                "safety_issue": "No", 
                "time_frame": "Blood gathering point : 0h, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 7h, 8h, 12h, 24h, 48h, 72h"
            }, 
            {
                "measure": "\u0394AUEC24, \u0394Emax, tEmax", 
                "safety_issue": "No", 
                "time_frame": "0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 48h, 72h"
            }
        ], 
        "source": "Dong-A Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "Dong-A ST Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Dong-A Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}